Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial

Annals of Oncology

Volumn 27, Issue 11, 2016, Pages 2137-2138

  Ceccarelli, G ^a   Schietroma, I ^a   Corano Scheri, G ^a   d'Ettorre, G ^a   Vullo, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DACOMITINIB; PROBIOTIC AGENT; QUINAZOLINONE DERIVATIVE;

HUMAN; LUNG TUMOR; NON SMALL CELL LUNG CANCER; TUMOR RECURRENCE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROBIOTICS; QUINAZOLINONES;

EID: 85040690090     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw298     Document Type: Letter

References (5)

1. Lacouture, M.E., Keefe, D.M., Sonis, S., et al. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol 27 (2016), 1712–1718.
2. Delia, P., Sansotta, G., Donato, V., et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 13 (2007), 912–915.
3. Selinger, C.P., Bell, A., Cairns, A., et al. ProbioticVSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. J Hosp Infect 84 (2013), 159–165.
4. Haarman, M., Knol, J., Quantitative real-time PCR assays to identify and quantify fecal Bifidobacterium species in infants receiving a prebiotic infant formula. Appl Environ Microbiol 71 (2005), 2318–2324.
5. Dhar, S., Seth, J., Parikh, D., Systemic side-effects of topical corticosteroids. Indian J Dermatol 59 (2014), 460–464.